HIGHTIDE integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation in both diseases.

Our Pipeline


New molecular entity: ionic salt of two active moieties

NAFLD/NASH (Non-Alcoholic Fatty Liver Disease / Non-Alcoholic Steatohepatitis)
NAFLD is one of the types of fatty liver due to causes other than excessive alcohol use. NASH is the most extreme form of NAFLD.
Learn more
PSC (Primary Sclerosing Cholangitis)
Chronic liver disease characterized by a progressive reduction or stoppage of bile flow with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts.
Learn more

Peptide analog of RegIII/PAP protein active fragment

Acute Pancreatitis
Pancreatitis is inflammation of the pancreas.
Learn more

An innovative fixed dose combination of two known compounds with clear differentiation for unmet clinical needs

Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) is a general term used to describe disorders that involve chronic inflammation of the digestive tract.
Learn more

We will contact you as soon as possible

© 2020 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy


Follow Us

© 2020 HighTide Therapeutics Inc.